Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study

European Respiratory Journal

Volumn 13, Issue 6, 1999, Pages 1351-1356

  Humbert, M ^a   Sanchez, O ^a   Fartoukh, M ^a   Jagot, J L ^a   Le Gall, C ^a   Sitbon, O ^a   Parent, F ^a   Simonneau, G ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Connective tissue diseases; Epoprostenol; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIURETIC AGENT; GOLD SALT; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; PROSTACYCLIN; VASODILATOR AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DIURETIC THERAPY; DRUG EFFECT; FEMALE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; LUNG EDEMA; MALE; ORAL DRUG ADMINISTRATION; OXYGEN THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; SEPSIS; SYNCOPE;

ADULT; ANTIHYPERTENSIVE AGENTS; CONNECTIVE TISSUE DISEASES; DRUG ADMINISTRATION SCHEDULE; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0032790301     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.1999.13f20.x     Document Type: Article

References (29)

1. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilatation in primary pulmonary hypertension. Circulation 1982; 66: 334-338.
2. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990; 112: 485-491.
3. Higenbottam TW, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; i: 1046-1047.
4. Barst RJ, Rubin LJ, McGoon MD, Caldwell EG, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415.
5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
6. McLaughlin VV, Genthner DE, Panella RN, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
7. Brundage BH. Pulmonary hypertension in collagen vascular disease. In: Fishman A, ed. The Pulmonary Circulation. Philadelphia University of Pennsylvania Press, 1990: pp. 353-358.
8. Brenot F, Simonneau G. Risk factors for primary pulmonary hypertension. In: Rubin L, Rich S, eds. Primary Pulmonary Hypertension. New York, Marcel Dekker, 1997: pp. 131-149.
9. Salemi R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977; 86: 394-399.
10. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75: 65-74.
11. Stupi AM, Steen VD, Owens GR, EL Barnes, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-524.
12. Koh ET, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-993.
13. Asherson RA, Higenbottam TW, Dihn-Xuan AT, Khamashta MA, Hughes GR. Pulmonary hypertension in a lupus clinic: experience with twenty four patients. J Rheumatol 1990; 17: 1292-1298.
14. Sato T, Matsubara O, Tanaka Y, Kasuga T. Association of Sjögren's syndrome with pulmonary hypertension: report of two cases and review of the literature. Hum Pathol 1993; 24: 199-205.
15. Rich S, Dantzer DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-223.
16. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 335: 111-117.
17. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995 ; 151: 384-389.
18. Dahl M, Chalmers A, Wade J, Calverley D, Munt B. Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J Rheumatol 1992; 19: 1807-1809.
19. Karmochkine M, Wechsler B, Godeau P, Brenot F, Jagot J-L, Simonneau G. Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheumatol Dis 1996; 55: 561-562.
20. Sitbon O, Humbert M, Jagot J-L, et al. Inhaled nitric oxide as a screening agent to safely identify responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270.
21. De la Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994; 37: 1528-1533.
22. Sitbon O, Gentil B, Humbert M, et al. Long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension: results from a large French monocenter study. Eur Respir J 1998; 12: Suppl. 28, 237s.
23. Khamashta MA, Cyadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
24. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824.
25. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997; 349: 1365.
26. Humbert M, Maître S, Capron F, Rain B, Musset D, Simonneau G. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157: 1681-1685.
27. Naeye RL. Pulmonary vascular lesions in systemic scleroderma. Dis Chest 1963; 44: 374-380.
28. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990; 21: 467-474.
29. Rademaker M, Cooke ED, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989; 298: 561-564.